8-KEarnings & ResultsExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Financial Results (Oct 19, 2006)

Filed October 19, 2006For Securities:EW

Summary

This 8-K filing from Edwards Lifesciences Corporation, dated October 19, 2006, announces the company's financial results for the third quarter of 2006. The primary purpose of this report is to provide investors with a formal disclosure of the company's performance during the period, which is detailed in an attached press release (Exhibit 99.1). While the 8-K itself is a procedural document, the core information investors will focus on is within the press release. This includes key financial metrics such as revenue, earnings per share, and any significant operational updates or forward-looking statements made by the company regarding its performance and business outlook. Investors should review Exhibit 99.1 for the specific details of the Q3 2006 financial results.

Key Highlights

  • 1Edwards Lifesciences Corp filed an 8-K on October 19, 2006.
  • 2The filing officially announces the company's financial results for the third quarter of 2006.
  • 3The detailed financial results are provided in an attached press release, Exhibit 99.1.
  • 4This report serves as a formal disclosure mechanism for material financial information.
  • 5The Chief Financial Officer, Thomas M. Abate, signed the filing.
  • 6Information furnished under Item 2.02, including Exhibit 99.1, is not deemed 'filed' except for specified portions of the press release.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and provide access to Edwards Lifesciences Corporation's financial results for the third quarter of 2006.

The specific financial details for the third quarter of 2006 are contained within the press release attached as Exhibit 99.1 to this 8-K filing.

No, according to the filing, only the information contained in the first two paragraphs of Exhibit 99.1 and pages 5 through 9 of the press release shall be considered 'filed' under the Exchange Act. The rest is furnished.

The report was signed by Thomas M. Abate, Corporate Vice President, Chief Financial Officer, and Treasurer of Edwards Lifesciences Corporation.